Evidence map›Paper›PMID 38920591›Full record

ArticleBiosensors2024

Design and Characterization of a Dual-Protein Strategy for an Early-Stage Assay of Ovarian Cancer Biomarker Lysophosphatidic Acid.

Katharina Davoudian, Sandro Spagnolo, Navina Lotay, Monika Satkauskas, Gábor Mészáros, Tibor Hianik, Zsófia Keresztes, Gilbert Walker, Michael Thompson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biosensors, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Katharina DavoudianDepartment of Chemistry, University of Toronto, 80 St. George Street, Toronto, ON M5S 3H6, Canada.ORCID 0000-0002-9675-4899
Sandro SpagnoloFaculty of Mathematics, Physics and Informatics, Comenius University, Mlynská dolina F1, 842 48 Bratislava, Slovakia.ORCID 0000-0002-2482-5643
Navina LotayDepartment of Chemistry, University of Toronto, 80 St. George Street, Toronto, ON M5S 3H6, Canada.ORCID 0000-0001-9355-9943
Monika SatkauskasDepartment of Chemistry, University of Toronto, 80 St. George Street, Toronto, ON M5S 3H6, Canada.ORCID 0000-0002-4361-4243
Gábor MészárosFunctional Interfaces Research Group, Institute of Materials and Environmental Chemistry, HUN-REN Research Centre for Natural Sciences, Magyar tudósok krt. 2., H-1117 Budapest, Hungary.ORCID 0000-0002-9247-6545
Tibor HianikFaculty of Mathematics, Physics and Informatics, Comenius University, Mlynská dolina F1, 842 48 Bratislava, Slovakia.ORCID 0000-0002-5906-0548
Zsófia KeresztesFunctional Interfaces Research Group, Institute of Materials and Environmental Chemistry, HUN-REN Research Centre for Natural Sciences, Magyar tudósok krt. 2., H-1117 Budapest, Hungary.ORCID 0000-0002-1126-4779
Gilbert WalkerDepartment of Chemistry, University of Toronto, 80 St. George Street, Toronto, ON M5S 3H6, Canada.
Michael ThompsonDepartment of Chemistry, University of Toronto, 80 St. George Street, Toronto, ON M5S 3H6, Canada.ORCID 0000-0002-1445-9918

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The overall 5-year survival rate of ovarian cancer (OC) is generally low as the disease is often diagnosed at an advanced stage of progression. To save lives, OC must be identified in its early stages when treatment is most effective. Early-stage OC causes the upregulation of lysophosphatidic acid (LPA), making the molecule a promising biomarker for early-stage detection. An LPA assay can additionally stage the disease since LPA levels increase with OC progression. This work presents two methods that demonstrate the prospective application for detecting LPA: the electromagnetic piezoelectric acoustic sensor (EMPAS) and a chemiluminescence-based iron oxide nanoparticle (IONP) approach. Both methods incorporate the protein complex gelsolin-actin, which enables testing for detection of the biomarker as the binding of LPA to the complex results in the separation of gelsolin from actin. The EMPAS was characterized with contact angle goniometry and atomic force microscopy, while gelsolin-actin-functionalized IONPs were characterized with transmission electron microscopy and Fourier transform infrared spectroscopy. In addition to characterization, LPA detection was demonstrated as a proof-of-concept in Milli-Q water, buffer, or human serum, highlighting various LPA assays that can be developed for the early-stage detection of OC.

Indexed as

Biomarkers, TumorLysophospholipidsOvarian NeoplasmsActinsBiosensing TechniquesEarly Detection of CancerFemaleGelsolinHumansActinsBiomarkers, TumorGelsolinlysophosphatidic acidLysophospholipidsactinantifouling linkeratomic force microscopychemiluminescenceEMPASgelsolinlysophosphatidic acidnanoparticlesovarian cancer

Identifiers

PMID38920591
PMCPMC11201771

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.